Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Structural basis for the targeting of complement anaphylatoxin C5a using a mixed L-RNA/L-DNA aptamer.

Yatime L, Maasch C, Hoehlig K, Klussmann S, Andersen GR, Vater A.

Nat Commun. 2015 Apr 22;6:6481. doi: 10.1038/ncomms7481.

2.

Crystal structure of a mirror-image L-RNA aptamer (Spiegelmer) in complex with the natural L-protein target CCL2.

Oberthür D, Achenbach J, Gabdulkhakov A, Buchner K, Maasch C, Falke S, Rehders D, Klussmann S, Betzel C.

Nat Commun. 2015 Apr 22;6:6923. doi: 10.1038/ncomms7923.

3.

Complement system modulation as a target for treatment of arrhythmogenic cardiomyopathy.

Mavroidis M, Davos CH, Psarras S, Varela A, C Athanasiadis N, Katsimpoulas M, Kostavasili I, Maasch C, Vater A, van Tintelen JP, Capetanaki Y.

Basic Res Cardiol. 2015 May;110(3):27. doi: 10.1007/s00395-015-0485-6. Epub 2015 Apr 8.

PMID:
25851234
4.

A novel CGRP-neutralizing Spiegelmer attenuates neurogenic plasma protein extravasation.

Hoehlig K, Johnson KW, Pryazhnikov E, Maasch C, Clemens-Smith A, Purschke WG, Vauléon S, Buchner K, Jarosch F, Khiroug L, Vater A, Klussmann S.

Br J Pharmacol. 2015 Jun;172(12):3086-98. doi: 10.1111/bph.13110. Epub 2015 Mar 27.

5.

SDF-1 inhibition targets the bone marrow niche for cancer therapy.

Roccaro AM, Sacco A, Purschke WG, Moschetta M, Buchner K, Maasch C, Zboralski D, Zöllner S, Vonhoff S, Mishima Y, Maiso P, Reagan MR, Lonardi S, Ungari M, Facchetti F, Eulberg D, Kruschinski A, Vater A, Rossi G, Klussmann S, Ghobrial IM.

Cell Rep. 2014 Oct 9;9(1):118-128. doi: 10.1016/j.celrep.2014.08.042. Epub 2014 Sep 25.

6.

The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization.

Hoellenriegel J, Zboralski D, Maasch C, Rosin NY, Wierda WG, Keating MJ, Kruschinski A, Burger JA.

Blood. 2014 Feb 13;123(7):1032-9. doi: 10.1182/blood-2013-03-493924. Epub 2013 Nov 25.

7.

A novel C5a-neutralizing mirror-image (l-)aptamer prevents organ failure and improves survival in experimental sepsis.

Hoehlig K, Maasch C, Shushakova N, Buchner K, Huber-Lang M, Purschke WG, Vater A, Klussmann S.

Mol Ther. 2013 Dec;21(12):2236-46. doi: 10.1038/mt.2013.178. Epub 2013 Jul 26.

8.

A mixed mirror-image DNA/RNA aptamer inhibits glucagon and acutely improves glucose tolerance in models of type 1 and type 2 diabetes.

Vater A, Sell S, Kaczmarek P, Maasch C, Buchner K, Pruszynska-Oszmalek E, Kolodziejski P, Purschke WG, Nowak KW, Strowski MZ, Klussmann S.

J Biol Chem. 2013 Jul 19;288(29):21136-47. doi: 10.1074/jbc.M112.444414. Epub 2013 Jun 6.

9.

Hematopoietic stem and progenitor cell mobilization in mice and humans by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12.

Vater A, Sahlmann J, Kröger N, Zöllner S, Lioznov M, Maasch C, Buchner K, Vossmeyer D, Schwoebel F, Purschke WG, Vonhoff S, Kruschinski A, Hübel K, Humphrey M, Klussmann S, Fliegert F.

Clin Pharmacol Ther. 2013 Jul;94(1):150-7. doi: 10.1038/clpt.2013.58. Epub 2013 Mar 19.

PMID:
23588307
10.

Targeting complement component 5a promotes vascular integrity and limits airway remodeling.

Khan MA, Maasch C, Vater A, Klussmann S, Morser J, Leung LL, Atkinson C, Tomlinson S, Heeger PS, Nicolls MR.

Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6061-6. doi: 10.1073/pnas.1217991110. Epub 2013 Mar 25.

11.

The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys.

Schwoebel F, van Eijk LT, Zboralski D, Sell S, Buchner K, Maasch C, Purschke WG, Humphrey M, Zöllner S, Eulberg D, Morich F, Pickkers P, Klussmann S.

Blood. 2013 Mar 21;121(12):2311-5. doi: 10.1182/blood-2012-09-456756. Epub 2013 Jan 24.

12.

Polyetheylenimine-polyplexes of Spiegelmer NOX-A50 directed against intracellular high mobility group protein A1 (HMGA1) reduce tumor growth in vivo.

Maasch C, Vater A, Buchner K, Purschke WG, Eulberg D, Vonhoff S, Klussmann S.

J Biol Chem. 2010 Dec 17;285(51):40012-8. doi: 10.1074/jbc.M110.178533. Epub 2010 Oct 20.

13.

Physicochemical stability of NOX-E36, a 40mer L-RNA (Spiegelmer) for therapeutic applications.

Maasch C, Buchner K, Eulberg D, Vonhoff S, Klussmann S.

Nucleic Acids Symp Ser (Oxf). 2008;(52):61-2. doi: 10.1093/nass/nrn031.

PMID:
18776253
14.
15.

Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer.

Helmling S, Maasch C, Eulberg D, Buchner K, Schröder W, Lange C, Vonhoff S, Wlotzka B, Tschöp MH, Rosewicz S, Klussmann S.

Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13174-9. Epub 2004 Aug 25.

16.

Protein kinase calpha targeting is regulated by temporal and spatial changes in intracellular free calcium concentration [Ca(2+)](i).

Maasch C, Wagner S, Lindschau C, Alexander G, Buchner K, Gollasch M, Luft FC, Haller H.

FASEB J. 2000 Aug;14(11):1653-63.

PMID:
10929000
17.

Differential expression of protein kinase C isoforms in streptozotocin-induced diabetic rats.

Kang N, Alexander G, Park JK, Maasch C, Buchwalow I, Luft FC, Haller H.

Kidney Int. 1999 Nov;56(5):1737-50.

18.

Requirement for protein kinase C in reactive oxygen species-induced apoptosis of vascular smooth muscle cells.

Li PF, Maasch C, Haller H, Dietz R, von Harsdorf R.

Circulation. 1999 Aug 31;100(9):967-73.

PMID:
10468528
19.

Calcium antagonists ameliorate ischemia-induced endothelial cell permeability by inhibiting protein kinase C.

Hempel A, Lindschau C, Maasch C, Mahn M, Bychkov R, Noll T, Luft FC, Haller H.

Circulation. 1999 May 18;99(19):2523-9.

PMID:
10330383
20.

The proliferative effect of vascular endothelial growth factor requires protein kinase C-alpha and protein kinase C-zeta.

Wellner M, Maasch C, Kupprion C, Lindschau C, Luft FC, Haller H.

Arterioscler Thromb Vasc Biol. 1999 Jan;19(1):178-85.

PMID:
9888881
21.

Intracellular targeting and protein kinase C in vascular smooth muscle cells: specific effects of different membrane-bound receptors.

Haller H, Maasch C, Lindschau C, Brachmann M, Buchner K, Luft FC.

Acta Physiol Scand. 1998 Dec;164(4):599-609.

PMID:
9887982
22.

Endothelial-cell permeability and protein kinase C in pre-eclampsia.

Haller H, Hempel A, Homuth V, Mandelkow A, Busjahn A, Maasch C, Drab M, Lindschau C, Jüpner A, Vetter K, Dudenhausen J, Luft FC.

Lancet. 1998 Mar 28;351(9107):945-9.

PMID:
9734941
23.

ICAM-1 antisense oligodesoxynucleotides prevent reperfusion injury and enhance immediate graft function in renal transplantation.

Dragun D, Tullius SG, Park JK, Maasch C, Lukitsch I, Lippoldt A, Gross V, Luft FC, Haller H.

Kidney Int. 1998 Aug;54(2):590-602.

24.

Antisense oligodesoxynucleotide strategies in renal and cardiovascular disease.

Haller H, Maasch C, Dragun D, Wellner M, von Janta-Lipinski M, Luft FC.

Kidney Int. 1998 Jun;53(6):1550-8. Review.

25.

Integrin-induced protein kinase Calpha and Cepsilon translocation to focal adhesions mediates vascular smooth muscle cell spreading.

Haller H, Lindschau C, Maasch C, Olthoff H, Kurscheid D, Luft FC.

Circ Res. 1998 Feb 9;82(2):157-65.

PMID:
9468186
26.

The Jak/Stat pathway and urokinase receptor signaling in human aortic vascular smooth muscle cells.

Dumler I, Weis A, Mayboroda OA, Maasch C, Jerke U, Haller H, Gulba DC.

J Biol Chem. 1998 Jan 2;273(1):315-21.

27.

High glucose concentrations increase endothelial cell permeability via activation of protein kinase C alpha.

Hempel A, Maasch C, Heintze U, Lindschau C, Dietz R, Luft FC, Haller H.

Circ Res. 1997 Sep;81(3):363-71.

PMID:
9285638

Supplemental Content

Loading ...
Support Center